Eberth Antibiotics - Outdated Package Inserts Create Patient Safety Risk
Summary
Dr. Friedrich Eberth Arzneimittel GmbH issued a Direct Healthcare Professional Communication (DHPC) via BfArM alerting that certain batches of nine antibiotic and antifungal products have outdated package inserts, creating a potential patient safety risk. Affected products include multiple strengths of cefazolin, cefotaxime, ceftazidime, ceftriaxone, levofloxacin, moxifloxacin, and voriconazole. Healthcare professionals are advised to discard outdated package inserts and refer to the current package inserts provided with the communication.
What changed
Dr. Friedrich Eberth Arzneimittel GmbH issued a Direct Healthcare Professional Communication (DHPC) via BfArM regarding outdated package inserts for nine specific antibiotic and antifungal products that may pose a patient safety risk. The affected products include Cefazolin Dr. Eberth 2 g, Cefotaxim Eberth 0.5 g, Ceftazidim Dr. Eberth 500 mg and 2 g, Ceftriaxon Eberth 1 g and 2 g, Levofloxacin Dr. Eberth 5 mg/ml, Moxifloxacin Eberth 400 mg/250 ml, and Voriconazol Eberth 200 mg.\n\nHealthcare providers should identify whether they hold stock of these affected batches, discard any outdated package inserts already received with the products, and refer to the current package inserts provided in the DHPC. This is a pharmacovigilance safety communication rather than a product recall, so affected products may remain in use with updated documentation.
What to do next
- Identify affected Eberth product batches in stock
- Discard outdated package inserts for listed products
- Refer to current package inserts provided in the DHPC
Archived snapshot
Apr 12, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Direct Healthcare Professional Communication (DHPC) on various medicinal products from Dr. Friedrich Eberth Arzneimittel GmbH: risk due to outdated package inserts
2026.03.30
Active substance: cefazolin, cefotaxime, ceftazidime, ceftriaxone, levofloxacin, moxifloxacin, voriconazol
The company Dr. Friedrich Eberth Arzneimittel GmbH informs about a potential risk to patient safety due to outdated package inserts for certain batches of the following medicinal products:
- Cefazolin Dr. Eberth 2 g Pulver zur Herstellung einer Injektions-/Infusionslösung
- Cefotaxim Eberth 0,5 g Pulver zur Herstellung einer Injektionslösung
- Ceftazidim Dr. Eberth 500 mg Pulver zur Herstellung einer Injektionslösung
- Ceftazidim Dr. Eberth 2 g Pulver zur Herstellung einer Injektions- bzw. Infusionslösung
- Ceftriaxon Eberth 1 g Pulver zur Herstellung einer Injektionslösung
- Ceftriaxon Eberth 2 g Pulver zur Herstellung einer Infusionslösung
- Levofloxacin Dr. Eberth 5 mg / ml Infusionslösung
- Moxifloxacin Eberth 400 mg /250 ml Infusionslösung
- Voriconazol Eberth 200 mg Pulver zur Herstellung einer Infusionslösung The company asks to discard the package inserts for the affected packages that have already been received and refer to the current package inserts as shown below.
Download DHPC/Information letter, DownloadVeroeffentlichtAmEN
2026.03.30
PDF, 2MB, File does not meet accessibility standards
Get daily alerts for BfArM Drug Safety Communications
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from BfArM.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when BfArM Drug Safety Communications publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.